
Merck Serono appoints R&D global head
pharmafile | July 16, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Luciano Rossetti, Merck Serono
Merck Serono the biopharma of division of US firm Merck has confirmed the appointment of Luciano Rossetti as its executive VP and global head of R&D.
Rossetti was previously senior VP of late stage development at MSD, which is the name for Merck outside of the US. In this position he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas.
Prior to joining MSD in 2006, Merck Serono says Rossetti was an internationally recognised academic scientist for 18 years.
“I’m thrilled to welcome Luciano Rossetti to Merck,” says Belén Garijo, president and chief executive at Merck Serono. “His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline.”
Rossetti will be based in Billerica, Massachusetts in the US, and share his time between Merck’s headquarters in Germany and Billerica – one of Merck Serono’s four global R&D hubs.
Related Content

Merck launches infertility programme in Uganda
Germany’s Merck has extended its infertility programme ‘Merck More than a Mother’ to Uganda, launching …
Merck rebrands as ‘science and technology’ company
Merck Group has rebranded to “reflect its transformation into a science and technology company”, and …
Merck KGaA reveals ASCO plans
Merck KGaA is the latest company to announce its slate for this year’s ASCO conference, …






